122 related articles for article (PubMed ID: 15817425)
21. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis.
Saito Y; Saito H; Tada S; Nakamoto N; Horikawa H; Kurita S; Kitamura K; Ebinuma H; Ishii H; Hibi T
Hepatogastroenterology; 2005; 52(65):1491-6. PubMed ID: 16201104
[TBL] [Abstract][Full Text] [Related]
22. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy.
Rühl R; Seidensticker M; Peters N; Mohnike K; Bornschein J; Schütte K; Amthauer H; Malfertheiner P; Pech M; Ricke J
Dig Dis; 2009; 27(2):189-99. PubMed ID: 19546558
[TBL] [Abstract][Full Text] [Related]
23. [Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres (author's transl)].
Magliulo E; Gagliardi B; Fiori GP
Med Klin; 1978 Jul; 73(28-29):1060-5. PubMed ID: 353464
[TBL] [Abstract][Full Text] [Related]
24. [Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].
Wu CH; Xu XY; Tian GS; Yu YY
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):390-3. PubMed ID: 16677548
[TBL] [Abstract][Full Text] [Related]
25. Amelioration of lead toxicity on rat liver with Vitamin C and silymarin supplements.
Shalan MG; Mostafa MS; Hassouna MM; El-Nabi SE; El-Refaie A
Toxicology; 2005 Jan; 206(1):1-15. PubMed ID: 15590105
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers.
Láng I; Nékám K; Deák G; Müzes G; Gonzales-Cabello R; Gergely P; Csomós G; Fehér J
Ital J Gastroenterol; 1990 Oct; 22(5):283-7. PubMed ID: 1983711
[TBL] [Abstract][Full Text] [Related]
27. DDB treatment of patients with chronic hepatitis.
Huber R; Hockenjos B; Blum HE
Hepatology; 2004 Jun; 39(6):1732-3. PubMed ID: 15185315
[TBL] [Abstract][Full Text] [Related]
28. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study.
Crosignani A; Budillon G; Cimino L; Del Vecchio Blanco C; Loguercio C; Ideo G; Raimondo G; Stabilini R; Podda M
Hepatogastroenterology; 1998; 45(23):1624-9. PubMed ID: 9840118
[TBL] [Abstract][Full Text] [Related]
29. [Clinical investigation of silymarin in chronic liver diseases (author's transl)].
Realini S; Gonvers JJ; Hofstetter JR
Schweiz Rundsch Med Prax; 1975 May; 64(19):595-8. PubMed ID: 51497
[No Abstract] [Full Text] [Related]
30. [Therapy of acute virus hepatitis with silymarin. Report of a controlled study].
Schmidt U; Dürr HK; Bode JC
Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():563-5. PubMed ID: 25535
[No Abstract] [Full Text] [Related]
31. Affect of silymarin on serum levels of ALT and GGT in ethanol induced hepatotoxicity in albino rats.
Habib-ur-Rehman M; Mahmood T; Salim T; Afzal N; Ali N; Iqbal J; Tahir M; Khan A
J Ayub Med Coll Abbottabad; 2009; 21(4):73-5. PubMed ID: 21067030
[TBL] [Abstract][Full Text] [Related]
32. Hepatoprotective and immunological effects of antioxidant drugs.
Láng I; Nékám K; González-Cabello R; Mũzes G; Gergely P; Fehér J
Tokai J Exp Clin Med; 1990 May; 15(2-3):123-7. PubMed ID: 1983370
[TBL] [Abstract][Full Text] [Related]
33. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.
Pockros PJ; Schiff ER; Shiffman ML; McHutchison JG; Gish RG; Afdhal NH; Makhviladze M; Huyghe M; Hecht D; Oltersdorf T; Shapiro DA
Hepatology; 2007 Aug; 46(2):324-9. PubMed ID: 17654603
[TBL] [Abstract][Full Text] [Related]
34. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases].
Fehér J; Deák G; Müzes G; Láng I; Niederland V; Nékám K; Kárteszi M
Orv Hetil; 1989 Dec; 130(51):2723-7. PubMed ID: 2574842
[TBL] [Abstract][Full Text] [Related]
35. Improved antifibrotic effect of a combination of verapamil and silymarin in rat-induced liver fibrosis.
Shafik AN; Khodeir MM; Gouda NA; Mahmoud ME
Arab J Gastroenterol; 2011 Sep; 12(3):143-9. PubMed ID: 22055593
[TBL] [Abstract][Full Text] [Related]
36. Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C.
Strickland GT; Tanamly MD; Tadros F; Labeeb S; Makld H; Nessim D; Mikhail N; Magder LS; Afdhal NH; Medhat A; Abdel-Hamid M
Dig Liver Dis; 2005 Jul; 37(7):542-3. PubMed ID: 15975544
[No Abstract] [Full Text] [Related]
37. [Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients].
Trinchet JC; Coste T; Lévy VG; Vivet F; Duchatelle V; Legendre C; Gotheil C; Beaugrand M
Gastroenterol Clin Biol; 1989; 13(2):120-4. PubMed ID: 2707520
[TBL] [Abstract][Full Text] [Related]
38. Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis.
de Avelar CR; Pereira EM; de Farias Costa PR; de Jesus RP; de Oliveira LPM
World J Gastroenterol; 2017 Jul; 23(27):5004-5017. PubMed ID: 28785154
[TBL] [Abstract][Full Text] [Related]
39. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
Fried MW; Navarro VJ; Afdhal N; Belle SH; Wahed AS; Hawke RL; Doo E; Meyers CM; Reddy KR;
JAMA; 2012 Jul; 308(3):274-82. PubMed ID: 22797645
[TBL] [Abstract][Full Text] [Related]
40. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results.
Tanamly MD; Tadros F; Labeeb S; Makld H; Shehata M; Mikhail N; Abdel-Hamid M; Shehata M; Abu-Baki L; Medhat A; Magder LS; Afdhal NH; Strickland GT
Dig Liver Dis; 2004 Nov; 36(11):752-9. PubMed ID: 15571006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
